Health Exchange Alert Weekly Report

Sen. Health Committee Stuck On 1332 Debate As CSR Deadline Looms

September 12, 2017
Senators on the health committee tried to gauge whether any action on 1332 waivers to make them easier for states to obtain and implement would cause premiums to rise or hurt people with pre-existing conditions during the third individual market stabilization hearing Tuesday (Sept.12). "[W]hile we've heard a lot of interesting proposals, I worry that many suggestions could wind up increasing out-of-pocket costs for patients and families -- when our principal goal in these hearings and in our bipartisan negotiations...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, news from FDA and much more.